Медицинские вопросы и проблемы подростков, больных муковисцидозом
68
Ramsey BW, Davies J, McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72
69
Rosenfeld M, Pepe MS, Longton G, Emerson J, FitzSimmons S, Morgan
70
Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88
71
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87
72
Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14
73
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
74
Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. J Cyst Fibros 2010; 9:332-8
75
VanDevanter DR, Wagener JS, Pasta DJ et al. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol 2010;45:1156-66
76
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
77
Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19
78
Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006; 174:7 80-6
79
Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006; 174:7 80-6
80
Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19
81
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
82
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
83
Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995; 48:1041-9
84
Kristidis P Bozon D, Corey M et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178-84
85
The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. New Engl J Med 1993; 329:1308-13
86
McKone EF, Emerson SS, Edwards KL et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671-6
87
McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130:1441-7
88
Sanders DB, Hoffman LR, Emerson J et al. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34
89
Wagener JS, VanDevanter DR, Pasta DJ, Regelmann W, Morgan WJ, Konstan MW. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2012. (In press) DOI: 10.1002/ ppul. 22652
90
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
91
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
92
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
93
Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol 2010; 45:450-8
94
Modi AC, Marciel KK, Slater SK, Drotar D, Quittner AQ. The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Children's Health Care 2008; 37:78-92
95
Vandenbranden SL, McMullen A, Schechter MS et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012;47:135-43
96
Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54
97
Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249-54
98
Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007;176:1084-9
99
Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ. The initiation of inhaled corticosteroid therapy in cystic fibrosis patients is associated with a slower rate of lung function decline. J Pediatr 2008; 153:746-51
100
Konstan MW, Wagener JS, Pasta DJ et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011;46:545-53
101
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
102
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
103
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
104
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
105
Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55
106
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
107
Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88
108
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87
109
Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55
110
VanDevanter DR, Rasouliyan LH, Murphy TM et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43:739-44
111
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
112
VanDevanter DR, Rasouliyan LH, Murphy TM et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43:739-44
113
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
114
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
115
Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011
116
Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011
117
Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros2009;8S:S15-S19
118
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
119
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
120
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
121
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
122
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
123
Schumacher KL, Meleis Al. Transition: a central concept in nursing. Image J NursSch 1994;26:119-27
124
Schumacher KL, Meleis Al. Transition: a central concept in nursing. Image J NursSch 1994;26:119-27
125
] Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9
126
World Health Organization. Child and adolescent health. Available at: http://www.searo.who.int/en/Section13/Section1245_4980.htm Accessed 19 September 2012
127
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
128
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
129
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
130
Brumfield K, Lansbury G. Experiences of adolescents with cystic fibrosis during their transition from pediatric to adult health care: a qualitative study of young Australian adults. Disabil Rehabil 2004;26:223-34
131
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
132
Eiser С Effects of chronic illness on children and their families. Adv Psychiatr Treat 1997; 3:204-10
133
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
134
Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9
135
Cowlard J. Cystic fibrosis: transition from paediatric to adult care. Nursing Standard 2003; 18(4):39-4
136
Viner R. Transition from paediatric to adult care. Bridging the gaps or passing the buck. Arch Dis Child 1999; 81:271-5
137
Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9
138
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
139
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
140
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
141
Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75
142
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
143
Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16
144
Kerem E, Conway S, Heijerman H; Concensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4:7-26
145
Smith LJ, McKay КО, van Asperen PR Selvadurai H, Fitzgerald DA. Normal development of the lung and premature birth. Paediatr Respir Rev 2010; 11:135-42
146
Esterly JR, Oppenheimer EH. Observations in cystic fibrosis of the pancreas. 3. Pulmonary lesions. Johns Hopkins Med J 1968; 122:94-101
147
Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982;106:303-11
148
Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976; 7:195-204
149
Chow CW, Landau LI, Taussig LM. Bronchial mucous glands in the newborn with cystic fibrosis. Eur J Pediatr 1982; 139:240-3
150
Larson JE, Delcarpio JB, Farberman MM, Morrow SL, Cohen JC. CFTR modulates lung secretory cell proliferation and differentiation. Am J Physiol Lung Cell Mol Physiol 2000; 279:L333-41
151
Davies LA, Varathalingam A, Painter H et al. Adenovirus-mediated in utero expression of CFTR does not improve survival of CFTR knockout mice. Mol Ther2008; 16:812-18
152
Weibel ER, Gomez DM. A principle for counting tissue structures on random sections. J Appl Physiol 1962; 17:343-8
153
Narayanan M, Owers-Bradley J, Beardsmore CS et al. Alveolarization continues during childhood and adolescence: new evidence from helium-3 magnetic resonance. Am J Respir Crit Care Med 2012; 185:186-91
154
Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15
155
Tarran R, Button B, Picher M et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005; 280:35751-9
156
de Vrankrijker AM, Wolfs TF, van der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010; 11:246-54. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011; 23:319-24
157
Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011; 23:319-24
158
Sibley CD, Surette MG. The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture. Can J Microbiol 2011;57:69-77
159
Williams HD, Davies JC. Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Thorax 2012; 67:465-7
160
Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011; 17:442-7
161
Asner S, Waters V, Solomon M et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012; 11:433-9
162
Waters V, Stanojevic S, Atenafu EG et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6
163
Sanders DB, Hoffman LR, Emerson J et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45:127-34
164
Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012;141:485-93
165
Armstrong DS, Grimwood K, Carlin JB et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197-204
166
Stoltz DA, Meyerholz DK, Pezzulo AA et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010;2:29-31
167
Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-91
168
Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialo GM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993;92:1875-80
169
RatnerAJ, Bryan R, Weber A et al. Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem 2001;276:19267-75
170
Knorre A, Wagner M, Schaefer HE, Colledge WH, Pahl HL. DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs. Biol Chem 2002;383:271-82
171
Bonfield TL, Konstan MW, Burfeind P Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the antiinflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995;13:257-61
172
Karp CL, Flick LM, Park KW et al. Defective lipoxin-mediated antiinflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5:388-92
173
Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. J Innate Immun 2010; 2:260-6
174
Hayes E, Pohl K, McElvaney NG, Reeves EF1 The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp 2011; 59:97-112
175
Hartl D, Latzin P Hordijk P et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13:1423-30
176
Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008;32:783-95
177
Hilliard TN, Regamey N, Shute JK et al. Airway remodelling in children with cystic fibrosis. Thorax 2007; 62:1074-80
178
Regamey N, Ochs M, Hilliard TN et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008; 177:837-13
179
Laguna ТА, Wagner BD, Starcher В et al. Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012;47:856-63
180
Regamey N, Tsartsali L, Hilliard TN et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012; 67:164-70
181
Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184:252-8
182
Xiao H, Li DX, Liu M. Knowledge translation: airway epithelial cell migration and respiratory diseases. Cell Mol Life Sci 2012. (In press) DOI: 10.1007/s00018-012-1044-z
183
Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010;298:L715-31
184
Rock JR, Hogan BL. Epithelial progenitor cells in lung development, maintenance, repair, and disease. Annu Rev Cell Dev Biol 2011; 27:493-512
185
Hegab AE, Ha VL, Gilbert JL et al. Novel stem/progenitor cell population from murine tracheal submucosal gland ducts with multipotent regenerative potential. Stem Cells 2011; 29:1283-93
186
Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 2001; 24:671-81
187
Fujino N, Kubo H, Suzuki T et al. Isolation of alveolar epithelial type II progenitor cells from adult human lungs. Lab Invest 2011; 91:363-78
188
Krause DS. Bone marrow-derived lung epithelial cells. Proc Am Thorac Soc 2008; 5:699-702
189
Legrand C, Gilles C, Zahm JM et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol 1999;146:517-29
190
Legrand C, Polette M, Tournier JM et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264:326-36
191
Xiao H, Li DX, Liu M. Knowledge translation: airway epithelial cell migration and respiratory diseases. Cell Mol Life Sci 2012. (In press) DOI: 10.1007/s00018-012-1044-z
192
Hajj R, Lesimple P Nawrocki-Raby B, Birembaut P Puchelle E, Coraux С Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis. J Pathol 2007;211:340-50
193
Trinh NT, Prive A, Maille E, Noel J, Brochiero E. EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. Am J Physiol Lung Cell Mol Physiol 2008; 295:L866-80
194
Trinh NT Bardou O, Prive A et al. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue. Eur Respir J 2012. (In press) DOI: 10.1183/09031936.00221711
